MicrobeWorld App

appsquarebannerad200x200

ASM Fellowships

Fellowship

Microbes After Hours

Watter-Supply-200x200-Banner

Click for more "Microbes After Hours" videos

Join MicrobeWorld

Subscribe via Email

subscribe

Featured Image

Featured Video

Ebola Virus explained

Supporters

ASM House 200X200

ICAAC 2010 - What Big Pharma Wants and What Biotech Can Offer

























As larger pharmaceutical companies have reduced focus on discovery and early development of antibacterials, smaller biotech companies have taken on a larger role in these earliest stages of antibacterial development, later licensing or selling the compound to the pharmaceutical company to complete development. Although this model has helped to partially resuscitate a diminishing antibacterial pipeline, is it the most effective model for the development of new drugs? Participants outline the advantages and pitfalls associated with this model as well as other proposed models for drug development and will also discuss what new drugs are currently in this pipeline. * Gary Noel, Johnson and Johnson, North Caldwell, NJ, United States * Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria

 
 

Comments (0)

Collections (1)

 

American Society for Microbiology
2012 1752 N Street, N.W. • Washington, DC 20036-2904 • (202) 737-3600
American Society For Microbiology © 2014   |   Privacy Policy   |   Terms of Use